Moreover, a phase II clinical trial over 60 months preliminarily validated the efficacy of the targeted vaccine nelipepimut‐S, which was developed for HER2‐low breast cancer, and only 5.6% of patients in the vaccine group experienced cancer recurrence compared with 25.9% in the control group [11]. This evidence concerns the gene ERBB2 and breast carcinoma.